Jazz Pharmaceuticals, Inc. is Dominating Europe Psychedelic Drugs Market in 2019

Europe Psychedelic Drugs Market is expected to grow at a healthy CAGR of 15.0% in the forecast period 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report at https://www.databridgemarketresearch.com/reports/europe-psychedelic-drugs-market

Psychedelic drugs market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased various strategic developments owing to favourable market scenario.

The major players dealing in psychedelic drugs market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio.

Jazz Pharmaceuticals, Inc. is the dominating player in the Europe psychedelic drugs market and the other players in the market are Johnson & Johnson Services, Inc., Celon Pharma SA, COMPASS, usonainstitute.org, Develco pharma schweiz ag , Doughlas pharmaceuticals limited , NeuroRX, Inc, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, LLC., AVADEL PHARMACEUTICALS, PLC among others.

Europe Psychedelic Drugs Market

Jazz Pharmaceuticals, Inc.:

Jazz Pharmaceuticals, Inc. headquartered in Dublin, Ireland was incorporated in 2013. The company is engaged in transforming bio-pharmaceutical discoveries into novel drug replacement drugs for the treatment of rare or complex diseases. The company is offering products under the departments of medicine (medicines, medicines safety, and treatment information), research (pipeline, clinical trials, expanded access, and individual scientific research). The company is constantly engaged in the production and development of psychedelic drugs.

  • In January 2020, Jazz Pharmaceuticals, Inc. received marketing authorization of soliumfetol (Sanosi) for excessive daytime sleepiness in adults with narcolepsy. This will help in the growth of the company.

It also has direct sales representatives and distributors in North America, Europe through its subsidiaries Jazz Pharmaceuticals, Inc. (US), Jazz Financing Eye Designed Activity Company (Ireland), Jazz Pharmaceuticals Ireland Limited (Ireland),  Jazz Capital Limited (Ireland), Celator Pharmaceuticals, Inc. (US) among others.